Gerald Friedland

8.7k total citations · 3 hit papers
89 papers, 6.6k citations indexed

About

Gerald Friedland is a scholar working on Infectious Diseases, Epidemiology and Virology. According to data from OpenAlex, Gerald Friedland has authored 89 papers receiving a total of 6.6k indexed citations (citations by other indexed papers that have themselves been cited), including 56 papers in Infectious Diseases, 45 papers in Epidemiology and 20 papers in Virology. Recurrent topics in Gerald Friedland's work include HIV/AIDS Research and Interventions (27 papers), HIV/AIDS drug development and treatment (21 papers) and HIV Research and Treatment (20 papers). Gerald Friedland is often cited by papers focused on HIV/AIDS Research and Interventions (27 papers), HIV/AIDS drug development and treatment (21 papers) and HIV Research and Treatment (20 papers). Gerald Friedland collaborates with scholars based in United States, South Africa and United Kingdom. Gerald Friedland's co-authors include Robert S. Klein, Catherine B. Small, Peter A. Selwyn, Ellie E. Schoenbaum, Diana Hartel, Carol Harris, Bernice Moll, Sten H. Vermund, Victor Lewis and Martin Lesser and has published in prestigious journals such as New England Journal of Medicine, JAMA and Annals of Internal Medicine.

In The Last Decade

Gerald Friedland

88 papers receiving 6.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Prospective Study of the Risk of Tuberculosis among Intravenous Drug Users with Human Immunodeficiency Virus Infection

1989 1.2k citations Peter A. Selwyn, Diana Hartel et al. New England Journal of Medicine profile →
Oral Candidiasis in High-Risk Patients as the Initial Manifestation of the Acquired Immunodeficiency Syndrome

1984 728 citations Robert S. Klein, Gerald Friedland et al. New England Journal of Medicine profile →
Timing of Initiation of Antiretroviral Drugs during Tuberculosis Therapy

2010 478 citations Gerald Friedland et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Gerald Friedland United States	38	4.0k	3.7k	1.2k	1.1k	913	89	6.6k
Robert S. Holzman United States	41	2.3k 0.6×	2.3k 0.6×	1.2k 1.0×	724 0.7×	502 0.5×	156	6.3k
Jonathan E. Kaplan United States	38	4.0k 1.0×	3.5k 0.9×	448 0.4×	1.3k 1.2×	511 0.6×	88	6.7k
Ida M. Onorato United States	41	4.2k 1.1×	3.7k 1.0×	1.6k 1.3×	562 0.5×	461 0.5×	101	6.4k
Ram Yogev United States	49	3.4k 0.8×	4.2k 1.2×	718 0.6×	1.5k 1.4×	1.3k 1.4×	298	9.1k
Andy I. M. Hoepelman Netherlands	53	4.1k 1.0×	5.3k 1.4×	759 0.6×	1.3k 1.2×	817 0.9×	255	10.5k
Christopher C. Whalen United States	46	4.3k 1.1×	3.2k 0.9×	1.3k 1.1×	738 0.7×	355 0.4×	174	6.5k
Edward N. Janoff United States	49	2.9k 0.7×	4.5k 1.2×	812 0.7×	1.2k 1.1×	644 0.7×	146	7.9k
Maurizio de Martino Italy	43	2.4k 0.6×	2.5k 0.7×	778 0.7×	797 0.8×	603 0.7×	244	6.2k
Roy D. Mugerwa Uganda	40	3.8k 0.9×	2.8k 0.8×	1.2k 1.0×	853 0.8×	338 0.4×	93	5.1k
Sheldon H. Landesman United States	47	3.5k 0.9×	3.1k 0.9×	432 0.4×	1.7k 1.6×	535 0.6×	122	6.4k

Countries citing papers authored by Gerald Friedland

Since Specialization

Citations

This map shows the geographic impact of Gerald Friedland's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gerald Friedland with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gerald Friedland more than expected).

Fields of papers citing papers by Gerald Friedland

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gerald Friedland. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gerald Friedland. The network helps show where Gerald Friedland may publish in the future.

Co-authorship network of co-authors of Gerald Friedland

This figure shows the co-authorship network connecting the top 25 collaborators of Gerald Friedland. A scholar is included among the top collaborators of Gerald Friedland based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gerald Friedland. Gerald Friedland is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bruce, R. Douglas, Peter Winkle, Joseph M. Custodio, et al.. (2013). The Pharmacokinetic and Pharmacodynamic Interactions Between Buprenorphine/Naloxone and Elvitegravir/Cobicistat in Subjects Receiving Chronic Buprenorphine/Naloxone Treatment. JAIDS Journal of Acquired Immune Deficiency Syndromes. 63(4). 480–484. 14 indexed citations

Shah, Neha, Prashini Moodley, Palav Babaria, et al.. (2011). Rapid Diagnosis of Tuberculosis and Multidrug Resistance by the Microscopic-Observation Drug-Susceptibility Assay. American Journal of Respiratory and Critical Care Medicine. 183(10). 1427–1433. 41 indexed citations

Shah, N. Sarita, Prashini Moodley, Palav Babaria, et al.. (2011). Increasing Drug Resistance in Extensively Drug-Resistant Tuberculosis, South Africa. Emerging infectious diseases. 17(3). 510–513. 48 indexed citations

Gandhi, Neel R., Sarita Shah, & Gerald Friedland. (2010). Antiretroviral Therapy for Control of the HIV-associated MDR and XDR Tuberculosis Epidemic in South Africa. American Journal of Respiratory and Critical Care Medicine. 182(12). 1568–1569. 2 indexed citations

Gandhi, Neel R., Neha Shah, Jason R. Andrews, et al.. (2009). HIV Coinfection in Multidrug- and Extensively Drug-Resistant Tuberculosis Results in High Early Mortality. American Journal of Respiratory and Critical Care Medicine. 181(1). 80–86. 245 indexed citations

Cornman, Deborah H., Susan M. Kiene, Sarah Christie, et al.. (2008). Clinic-Based Intervention Reduces Unprotected Sexual Behavior Among HIV-Infected Patients in KwaZulu-Natal, South Africa: Results of a Pilot Study. JAIDS Journal of Acquired Immune Deficiency Syndromes. 48(5). 553–560. 61 indexed citations

Gandhi, Neel R., Anthony P. Moll, Umesh Lalloo, et al.. (2008). Successful Integration of Tuberculosis and HIV Treatment in Rural South Africa: The Sizonq'oba Study. JAIDS Journal of Acquired Immune Deficiency Syndromes. 50(1). 37–43. 78 indexed citations

Bruce, R. Douglas, Frederick L. Altice, & Gerald Friedland. (2008). Pharmacokinetic drug interactions between drugs of abuse and antiretroviral medications: implications and management for clinical practice. Expert Review of Clinical Pharmacology. 1(1). 115–127. 16 indexed citations

Kozal, Michael J., K. Rivet Amico, Jennifer Chiarella, et al.. (2006). A Population‐Based and Longitudinal Study of Sexual Behavior and Multidrug‐Resistant HIV Among Patients in Clinical Care. Journal of the International AIDS Society. 8(1). 72–72. 12 indexed citations

10.

Struthers, Helen, et al.. (2006). Development and Assessment of an Innovative Culturally Sensitive Educational Videotape to Improve Adherence to Highly Active Antiretroviral Therapy in Soweto, South Africa. JAIDS Journal of Acquired Immune Deficiency Syndromes. 43(Supplement 1). S142–S148. 33 indexed citations

11.

Bruce, R. Douglas, Frederick L. Altice, Marc N. Gourevitch, & Gerald Friedland. (2006). Pharmacokinetic Drug Interactions Between Opioid Agonist Therapy and Antiretroviral Medications. JAIDS Journal of Acquired Immune Deficiency Syndromes. 41(5). 563–572. 90 indexed citations

12.

Friedland, Gerald. (1995). FDA Approves d4T as Alternative to AZT, ddI, or ddC. Journal watch. 1995. 1 indexed citations

13.

O’Dowd, Mary, et al.. (1993). A prospective four-year follow-up of neuropsychological function in HIV seropositive and seronegative methadone-maintained patients. General Hospital Psychiatry. 15(6). 351–359. 21 indexed citations

14.

O’Dowd, Mary, et al.. (1993). Association of Baseline Neuropsychological Function and Progression of Illness Over 4 Years in HIV-Seropositive Individuals. Psychosomatics. 34(6). 502–505. 1 indexed citations

15.

Greenberg, Alan E., P. Thomas, Sheldon H. Landesman, et al.. (1992). The spectrum of HIV-1-related disease among outpatients in New York City. AIDS. 6(8). 849–860. 40 indexed citations

16.

McKegney, F. Patrick, Mary O’Dowd, Cheryl Feiner, et al.. (1990). A prospective comparison of neuropsychologic function in HIV-seropositive and seronegative methadone-maintained patients. AIDS. 4(6). 565–570. 48 indexed citations

17.

Friedland, Gerald, et al.. (1989). Cervical and vaginal squamous cell abnormalities in women infected with human immunodeficiency virus.. PubMed. 2(6). 570–5. 72 indexed citations

18.

Selwyn, Peter A., Diana Hartel, Victor Lewis, et al.. (1989). A Prospective Study of the Risk of Tuberculosis among Intravenous Drug Users with Human Immunodeficiency Virus Infection. New England Journal of Medicine. 320(9). 545–550. 1170 indexed citations breakdown →

19.

McGuire, Glenn, et al.. (1988). Hospice care of the intravenous drug user AIDS patient in a skilled nurse facility.. PubMed. 1(4). 375–80. 5 indexed citations

20.

Selwyn, Peter A., Anat R. Feingold, Diana Hartel, et al.. (1988). Increased risk of bacterial pneumonia in HIV-infected intravenous drug users without AIDS. AIDS. 2(4). 267–272. 180 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact